Glucagon-like peptide 1 (GLP-1): An intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential

被引：109

作者：

Holst, JJ ^{[1
]}

机构：

[1] Univ Copenhagen, Panum Inst, Dept Phys Med, DK-2200 Copenhagen N, Denmark

来源：

TRENDS IN ENDOCRINOLOGY AND METABOLISM | 1999年 / 10卷 / 06期

关键词：

D O I：

10.1016/S1043-2760(99)00157-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The incretin hormone, glucagon-like peptide I (GLP-1) has many actions, namely: (I) it enhances all steps of insulin biosynthesis and potentiates glucose-induced secretion; (2) it seems to have trophic effects on pancreatic cells; (3) it inhibits glucagon secretion; (4) it inhibits hepatic glucose production and lowers blood glucose, but does not produce severe hypoglycaemia; (5) it inhibits postprandial gastrointestinal motility land secretion; and (6) it reduces appetite and food intake. Because of this, current research is focusing upon development of a clinically practicable therapy for type 2 diabetes mellitus based on GLP-1.

引用

页码：229 / 235

页数：7

共 75 条

[1] OXYNTOMODULIN (GLICENTIN-(33-69)) - PHARMACOKINETICS, BINDING TO LIVER-CELL MEMBRANES, EFFECTS ON ISOLATED PERFUSED PIG PANCREAS, AND SECRETION FROM ISOLATED PERFUSED LOWER SMALL-INTESTINE OF PIGS [J].

BALDISSERA, FGA ;

HOLST, JJ ;

KNUHTSEN, S ;

HILSTED, L ;

NIELSEN, OV .

REGULATORY PEPTIDES, 1988, 21 (1-2) :151-166

[2] THE BIOLOGICAL SIGNIFICANCE OF ENTEROGLUCAGON - PRESENT STATUS [J].

BATAILLE, D ;

JARROUSSE, C ;

KERVRAN, A ;

DEPIGNY, C ;

DUBRASQUET, M .

PEPTIDES, 1986, 7 :37-42

[3] HAMSTER PREPROGLUCAGON CONTAINS THE SEQUENCE OF GLUCAGON AND 2 RELATED PEPTIDES [J].

BELL, GI ;

SANTERRE, RF ;

MULLENBACH, GT .

NATURE, 1983, 302 (5910) :716-718

[4] EXON DUPLICATION AND DIVERGENCE IN THE HUMAN PREPROGLUCAGON GENE [J].

BELL, GI ;

SANCHEZPESCADOR, R ;

LAYBOURN, PJ ;

NAJARIAN, RC .

NATURE, 1983, 304 (5924) :368-371

[5] Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients [J].

Creutzfeldt, WOC ;

Orskov, C ;

Kleine, N ;

Holst, JJ ;

Willms, B ;

Nauck, MA .

DIABETES CARE, 1996, 19 (06) :580-586

[6] Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig [J].

Deacon, CF ;

Hughes, TE ;

Holst, JJ .

DIABETES, 1998, 47 (05) :764-769

[7] Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity [J].

Deacon, CF ;

Knudsen, LB ;

Madsen, K ;

Wiberg, FC ;

Jacobsen, O ;

Holst, JJ .

DIABETOLOGIA, 1998, 41 (03) :271-278

[8] BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS [J].

DEACON, CF ;

NAUCK, MA ;

TOFTNIELSEN, M ;

PRIDAL, L ;

WILLMS, B ;

HOLST, JJ .

DIABETES, 1995, 44 (09) :1126-1131

[9] DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO [J].

DEACON, CF ;

JOHNSEN, AH ;

HOLST, JJ .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) :952-957

[10] Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans - Studies with the antagonist exendin 9-39 [J].

Edwards, CMB ;

Todd, JF ;

Mahmoudi, M ;

Wang, ZL ;

Wang, RM ;

Ghatei, MA ;

Bloom, SR .

DIABETES, 1999, 48 (01) :86-93

← 1 2 3 4 5 6 7 8 →